Effects of Peri-Conception and Pregnancy Glycemic Variability on Pregnancy and Perinatal Complications in Type 1 Diabetes: A Pilot Study

Abstract

Background Not much is known about the effects of glycemic variability (GV) during the pre- and periconception period on pregnancy/perinatal complications. GV could potentially contribute to identification of high-risk pregnancies in women with type 1 diabetes.

Methods An explorative retrospective cohort study was conducted between January 2014 and May 2019. Glucose data were retrieved from electronic patient charts. Pre-/periconceptional GV and GV during all three trimesters was expressed as mean glucose, standard deviation (SD), Coefficient of Variation (CV), High Blood Glucose Index (HBGI), Low Blood Glucose Index (LBGI) and Average Daily Risk Range (ADRR). Maternal and neonatal complications were summarized using a composite total complication score. Binary logistic regression analyses were conducted to assess associations between the GV measures and a total complication score>3, a maternal complication score>1 and a neonatal complication score>1.

Results Of 63 eligible women, 29 women (38 pregnancies) were included. Women in the group with a total complication score>3 had a significantly higher ADRR at conception (OR 1.1, CI 1.0–1.2, p=0.048). No statistically significant correlations between complication score and any other GV metric besides the ADRR were found. Although not significant, in the group with a complication score>3, odds ratios>1 were found for SD in trimester 1 (OR 1.6, CI 0.6–4.5, p=0.357) and trimester 2 (OR 1.8, CI 0.5–6.2, p=0.376).

Conclusions Presence of a positive association between GV and pregnancy and perinatal complications depends on which pregnancy period is assessed and the GV metrics that are used.

Key words

Type 1 diabetes - Pregnancy - Glucose Variability - Continuous Glucose Monitoring

Publication History

Received: 12 May 2021
Received: 28 February 2022

Accepted: 07 March 2022

Accepted Manuscript online:
14 March 2022

Article published online:
21 November 2022

• References

• 1 Evers IM, de Valk HW, Visser GH. Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands. BMJ (Clinical research ed) 2004; 328: 915 DOI: 10.1136/bmj.38043.583160.EE.
• 2 Persson M, Norman M, Hanson U. Obstetric and perinatal outcomes in type 1 diabetic pregnancies: A large, population-based study. Diabetes care 2009; 32: 2005-2009 DOI: 10.2337/dc09-0656.
• 3 Feig DS, Hwee J, Shah BR. et al. Trends in incidence of diabetes in pregnancy and serious perinatal outcomes: a large, population-based study in Ontario, Canada, 1996-2010. Diabetes care 2014; 37: 1590-1596 DOI: 10.2337/dc13-2717.
• 4 Buschur EO, Polsky S. Type 1 Diabetes: Management in Women From Preconception to Postpartum. The Journal of clinical endocrinology and metabolism 2020; DOI: 10.1210/clinem/dgaa931. doi:10.1210/clinem/dgaa931
• 5 Feldman AZ, Brown FM. Management of Type 1 Diabetes in Pregnancy. Current diabetes reports 2016; 16: 76 DOI: 10.1007/s11892-016-0765-z.
• 6 Temple RC, Aldridge VJ, Murphy HR. Prepregnancy care and pregnancy outcomes in women with type 1 diabetes. Diabetes care 2006; 29: 1744-1749 DOI: 10.2337/dc05-2265.
• 7 Holmes VA, Young IS, Patterson CC. et al. Optimal glycemic control, pre-eclampsia, and gestational hypertension in women with type 1 diabetes in the diabetes and pre-eclampsia intervention trial. Diabetes care 2011; 34: 1683-1688 DOI: 10.2337/dc11-0244.
• 8 Maresh MJ, Holmes VA, Patterson CC. et al. Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes. Diabetes care 2015; 38: 34-42 DOI: 10.2337/dc14-1755.
• 9 Jensen DM, Korsholm L, Ovesen P. et al. Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes care 2009; 32: 1046-1048 DOI: 10.2337/dc08-2061.
• 10 Murphy H. Planning for pregnancy. Retrieved from URL: https://abcd.care/resource/planning-pregnancy Accessed 7-3-2022
• 11 Rosenn BM, Miodovnik M, Holcberg G. et al. Hypoglycemia: the price of intensive insulin therapy for pregnant women with insulin-dependent diabetes mellitus. Obstetrics and gynecology 1995; 85: 417-422 DOI: 10.1016/0029-7844(94)00415-a.
• 12 Kerssen A, Evers IM, de Valk HW. et al. Poor glucose control in women with type 1 diabetes mellitus and ‘safe’ hemoglobin A1c values in the first trimester of pregnancy. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet 2003; 13: 309-313 DOI: 10.1080/jmf.13.5.309.313.
• 13 Monnier L, Colette C, Schlienger JL. et al. Glucocentric risk factors for macrovascular complications in diabetes: Glucose ‘legacy’ and ‘variability’-what we see, know and try to comprehend. Diabetes & metabolism 2019; 45: 401-408 DOI: 10.1016/j.diabet.2019.01.007.
• 14 ter Braak EW, Evers IM, Willem Erkelens D. et al. Maternal hypoglycemia during pregnancy in type 1 diabetes: maternal and fetal consequences. Diabetes/metabolism research and reviews 2002; 18: 96-105 DOI: 10.1002/dmrr.271.
• 15 Kilpatrick ES, Rigby AS, Atkin SL. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes care 2008; 31: 2198-2202 DOI: 10.2337/dc08-0864.
• 16 Kovatchev B. Glycemic Variability: Risk Factors, Assessment, and Control. Journal of diabetes science and technology 2019; 13: 627-635 DOI: 10.1177/1932296819826111.
• 17 Yamamoto J, Murphy H. Benefits of Real-Time Continuous Glucose Monitoring in Pregnancy. Diabetes technology & therapeutics 2021; DOI: 10.1089/dia.2020.0667.
• 18 Feig DS, Donovan LE, Corcoy R. et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet (London, England) 2017; 390: 2347-2359 DOI: 10.1016/s0140-6736(17)32400-5.
• 19 Perea V, Giménez M, Amor AJ. et al. Prepregnancy care in women with type 1 diabetes improves HbA(1c) and glucose variability without worsening hypoglycaemia time and awareness: Glycaemic variability during prepregnancy care. Diabetes research and clinical practice 2019; 154: 75-81 DOI: 10.1016/j.diabres.2019.06.015.
• 20 Murphy HR. Continuous glucose monitoring targets in type 1 diabetes pregnancy: every 5% time in range matters. Diabetologia 2019; 62: 1123-1128 DOI: 10.1007/s00125-019-4904-3.
• 21 Kovatchev BP, Otto E, Cox D. et al. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes care 2006; 29: 2433-2438 DOI: 10.2337/dc06-1085.
• 22 Herman D, Lor KY, Qadree A. et al. Composite adverse outcomes in obstetric studies: a systematic review. BMC pregnancy and childbirth 2021; 21: 107 DOI: 10.1186/s12884-021-03588-w.
• 23 Hoftiezer L, Hukkelhoven CW, Hogeveen M. et al. Defining small-for-gestational-age: prescriptive versus descriptive birthweight standards. European journal of pediatrics 2016; 175: 1047-1057 DOI: 10.1007/s00431-016-2740-8.
• 24 Perined. Hoftiezer birth weight percentiles. Retrieved from URL: https://www.perined.nl/geboortegewichtcurven Accessed 7-3-2022
• 25 Kovatchev BP. Metrics for glycaemic control – from HbA(1c) to continuous glucose monitoring. Nature reviews Endocrinology 2017; 13: 425-436 DOI: 10.1038/nrendo.2017.3.
• 26 Kovatchev BP, Cox DJ, Gonder-Frederick LA. et al. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes care 1998; 21: 1870-1875 DOI: 10.2337/diacare.21.11.1870.
• 27 Monnier L, Colette C, Wojtusciszyn A. et al. Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes. Diabetes care 2017; 40: 832-838 DOI: 10.2337/dc16-1769.
• 28 Raman P, Shepherd E, Dowswell T. et al. Different methods and settings for glucose monitoring for gestational diabetes during pregnancy. The Cochrane database of systematic reviews 2017; 10: Cd011069 DOI: 10.1002/14651858.CD011069.pub2.
• 29 Goldman-Wohl D, Gamliel M, Mandelboim O. et al. Learning from experience: cellular and molecular bases for improved outcome in subsequent pregnancies. American journal of obstetrics and gynecology 2019; 221: 183-193 DOI: 10.1016/j.ajog.2019.02.037.
• 30 Murphy HR, Howgate C, O’Keefe J. et al. Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study. The lancet Diabetes & endocrinology 2021; DOI: 10.1016/s2213-8587(20)30406-x.
• 31 Kerssen A, de Valk HW, Visser GH. Increased second trimester maternal glucose levels are related to extremely large-for-gestational-age infants in women with type 1 diabetes. Diabetes care 2007; 30: 1069-1074 DOI: 10.2337/dc05-1985.
• 32 Herranz L, Pallardo LF, Hillman N. et al. Maternal third trimester hyperglycaemic excursions predict large-for-gestational-age infants in type 1 diabetic pregnancy. Diabetes research and clinical practice 2007; 75: 42-46 DOI: 10.1016/j.diabres.2006.05.019.
• 33 Dalfrà MG, Chilelli NC, Di Cianni G. et al. Glucose Fluctuations during Gestation: An Additional Tool for Monitoring Pregnancy Complicated by Diabetes. International journal of endocrinology 2013; 2013: 279021 DOI: 10.1155/2013/279021.
• 34 Law GR, Ellison GT, Secher AL. et al. Analysis of Continuous Glucose Monitoring in Pregnant Women With Diabetes: Distinct Temporal Patterns of Glucose Associated With Large-for-Gestational-Age Infants. Diabetes care 2015; 38: 1319-1325 DOI: 10.2337/dc15-0070.
• 35 Dalfrà MG, Sartore G, Di Cianni G. et al. Glucose variability in diabetic pregnancy. Diabetes technology & therapeutics 2011; 13: 853-859 DOI: 10.1089/dia.2010.0145.
• 36 McGrath RT, Glastras SJ, Seeho SK. et al. Association Between Glycemic Variability, HbA(1c), and Large-for-Gestational-Age Neonates in Women With Type 1 Diabetes. Diabetes care 2017; 40: e98-e100 DOI: 10.2337/dc17-0626.
• 37 Scott EM, Feig DS, Murphy HR. et al. Continuous Glucose Monitoring in Pregnancy: Importance of Analyzing Temporal Profiles to Understand Clinical Outcomes. Diabetes care 2020; 43: 1178-1184 DOI: 10.2337/dc19-2527.
• 38 Kristensen K, Ögge LE, Sengpiel V. et al. Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies. Diabetologia 2019; 62: 1143-1153 DOI: 10.1007/s00125-019-4850-0.
• 39 Gupta R, Khoury J, Altaye M. et al. Glycemic Excursions in Type 1 Diabetes in Pregnancy: A Semiparametric Statistical Approach to Identify Sensitive Time Points during Gestation. Journal of diabetes research 2017; 2017: 2852913 DOI: 10.1155/2017/2852913.
• 40 Kerssen A, de Valk HW, Visser GH. Day-to-day glucose variability during pregnancy in women with Type 1 diabetes mellitus: glucose profiles measured with the Continuous Glucose Monitoring System. BJOG: an international journal of obstetrics and gynaecology 2004; 111: 919-924 DOI: 10.1111/j.1471-0528.2004.00203.x.
• 41 Rodbard D. Standardization versus customization of glucose reporting. Diabetes technology & therapeutics 2013; 15: 439-443 DOI: 10.1089/dia.2013.0116.
• 42 Buschur ESB, Barbour LA. Diabetes In Pregnancy. 2018. In Endotext. Retrieved from URL: https://www.ncbi.nlm.nih.gov/books/NBK279010/Accessed 7-3-2022
• 43 Fraser RB, Waite SL, Wood KA. et al. Impact of hyperglycemia on early embryo development and embryopathy: in vitro experiments using a mouse model. Human reproduction (Oxford, England) 2007; 22: 3059-3068 DOI: 10.1093/humrep/dem318.
• 44 Li R, Chase M, Jung SK. et al. Hypoxic stress in diabetic pregnancy contributes to impaired embryo gene expression and defective development by inducing oxidative stress. American journal of physiology Endocrinology and metabolism 2005; 289: E591-E599 DOI: 10.1152/ajpendo.00441.2004.
• 45 Brown HM, Green ES, Tan TCY. et al. Periconception onset diabetes is associated with embryopathy and fetal growth retardation, reproductive tract hyperglycosylation and impaired immune adaptation to pregnancy. Scientific reports 2018; 8: 2114 DOI: 10.1038/s41598-018-19263-8.
• 46 Hoffman RP. Sympathetic mechanisms of hypoglycemic counterregulation. Current diabetes reviews 2007; 3: 185-193 DOI: 10.2174/157339907781368995.
• 47 Nepomnaschy PA, Welch KB, McConnell DS. et al. Cortisol levels and very early pregnancy loss in humans. Proceedings of the National Academy of Sciences of the United States of America 2006; 103: 3938-3942 DOI: 10.1073/pnas.0511183103.
• 48 Wu J, Kong S, Guo C. et al. An exaggerated epinephrine-adrenergic receptor signaling impairs uterine decidualization in mice. Reproductive toxicology (Elmsford, NY) 2019; 90: 109-117 DOI: 10.1016/j.reprotox.2019.09.003.
• 49 Bartho LA, Holland OJ, Moritz KM. et al. Maternal corticosterone in the mouse alters oxidative stress markers, antioxidant function and mitochondrial content in placentas of female fetuses. The Journal of physiology 2019; 597: 3053-3067 DOI: 10.1113/jp277815.
• 50 Simmons D. Adverse pregnancy outcomes in women with type 1 or type 2 diabetes. The lancet Diabetes & endocrinology 2021; DOI: 10.1016/s2213-8587(20)30427-7.